Home › Trials › NCT06424327

Registry for individuals diagnosed with lung cancer

Pulmonary Segmentectomy for Lung Cancer: A Real-World International Registry-TSOG 108

Memorial Sloan Kettering Cancer Center · NCT06424327

This study is collecting information from people with stage I lung cancer who are having surgery to see how they feel before and after the procedure to improve future treatments and care.

Quick facts

Study typeObservational
Enrollment600 (estimated)
Ages18 Years and up
SexAll
SponsorMemorial Sloan Kettering Cancer Center (other)
Drugs / interventionschemotherapy, radiation
Locations15 sites (Chicago, Illinois and 14 other locations)
Trial IDNCT06424327 on ClinicalTrials.gov

What this trial studies

This observational study aims to collect data from participants diagnosed with stage I lung cancer who are undergoing segmentectomy. Participants will complete questionnaires before surgery, and at two intervals post-surgery (2-4 weeks and 6 months). The study focuses on gathering patient-reported outcomes to better understand the experiences and recovery of lung cancer patients. The data collected will help inform future treatment approaches and patient care strategies.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with a clinical stage I lung tumor suitable for segmentectomy.

Not a fit: Patients with lung cancer not suitable for segmentectomy or those with advanced stages of lung cancer may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance understanding of patient experiences and improve post-surgical care for lung cancer patients.

How similar studies have performed: While observational studies on lung cancer exist, this specific registry approach focusing on patient-reported outcomes is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age ≥18 years
* Clinical Stage I with suspected NSCLC, classified preoperatively based on the AJCC TNM staging manual, 9th edition o Note: Tissue diagnosis of NSCLC is not required before enrollment. A pathologic diagnosis of NSCLC may be confirmed preoperatively with biopsy, intraoperatively with frozen section, or postoperatively on final pathology

Exclusion Criteria:

* Actively receiving lung cancer treatment or a history of lung cancer in the previous 5 years
* History of chemotherapy or radiation therapy for a previous lung cancer
* Synchronous secondary cancer in the lung or elsewhere in the body at the time of surgery
* Carcinoid tumors
* History of other malignancies within the past 3 years, with the exception of non-melanoma skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix
* Actively receiving treatment for other malignancies
* Cases of lobectomy in conjunction with segmentectomy from another lobe and ≥2 segmentectomies from different lobes either en bloc or separate will be excluded from the primary analysis.

  * Multi-segmental resection from the same lobe is not a criterion for exclusion.

Where this trial is running

Chicago, Illinois and 14 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Lung Cancer, Lung Cancer Stage I, lung cancer, lung cancer stage 1, segmentectomy, Memorial Sloan Kettering Cancer Center, 24-127

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.